Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?

Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) offer investors the chance to invest in one of today's highest-potential industries: weight loss drugs. The market for these products, worth about $28 billion right now, is forecast to grow to $95 billion by 2030, according to Goldman Sachs Research. And already, weight loss drugs have been supercharging the revenue of market leaders Lilly and Novo Nordisk.Viking hasn't yet launched a weight loss drug, but it has candidates in phase 2 and phase 3 trials, and has reported great results so far. For investors, Lilly and Viking have brought in triple-digit gains over the past three years, though both stocks have stumbled in more recent times. Now, moving forward, which is the best growth opportunity according to Wall Street? Let's find out.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool